Pharma industry serves best as underwriter of healthcare providers' efforts
The success in getting patients on therapy, and keeping them there for chronic conditions, is a well-known goal of both the biopharma industry and of healthcare providers and payers; better adherence is a win-win all around in better care and lower overall costs. Now, in a recently released study and an educational session held on Capitol Hill on March 1, NEHI (formerly known as the New England Healthcare Institute; nehi.net), a private-public policy consortium, is saying "the table is set" for managing better programs. Effective technologies and processes are becoming known, and the Patient Protection and Affordable Care Act is putting medication adherence on the priority list of quality measures by which providers will be evaluated.
"Efforts such as medical homes, the ability to review all the medications a patient is on through the electronic health record (EHR) data, and funding for medication therapy management (MTM) by pharmacists show great promise," says Tom Hubbard, senior policy director at NEHI. "Now the challenge is to connect these pieces in a coordinated manner."
Biopharma supports medication adherence directly, through coupon programs, patient support and education, and innovations in packaging. "Smart pillboxes and similar telehealth innovations can make a difference," says Hubbard. He also cites the clinical research performed with pharma support to develop adherence estimators and screening systems to predict adherence problems. But overall, says the NEHI report, the heart of medication adherence efforts should reside among primary care providers and pharmacists, who can deal with specific patient needs and who can access details on the medical condition of the patient. (Left unsaid, but a factor in this dynamic, is the criticism pharma companies suffer from stakeholders who believe pharma's motivation is simply to sell more pills, and from privacy advocates who believe that the pharma industry should not be a party to a patient's medical care.)
NEHI's report, "Roadmap to Improved Patient Medication Adherence," is available at NIHI's website. The Capitol Hill session was held, in part, to support legislative efforts by Senator Kay Hagan's (D- NC) bill, "Medication Therapy Improvement Act of 2011," (S.274), currently in committee. Hubbard says that next steps by NEHI will be to develop policy guidelines for care coordination.
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.
Study Connects COVID-19 Treatment Disparities to Gaps in Testing and Virtual Access
July 11th 2025New research finds that nearly half of the racial and ethnic disparities in outpatient COVID-19 antiviral prescriptions stem from encounter-level care barriers, such as limited access to rapid tests and telehealth, which emphasizes the need for systemic and practice-level reforms.